Table 1.
Isocitrate Dehydrogenase-Wild-Type Newly Diagnosed Primary Glioblastoma Patient Characteristics Using Imputed Data; the Ohio Brain Tumor Study (OBTS) and the University of California San Francisco (UCSF), 2007–2017
| OBTS (training set) (N = 179) | UCSF (validation set) (N = 122) | P-value | |
|---|---|---|---|
| Age at diagnosis (mean (SD)) [Range] | 63.02 (10.98) [29–88] | 60.90 (11.28) [24–85] | .104 |
| Sex (N (%)) | .180 | ||
| Male | 119 (66.5) | 71 (58.2) | |
| Female | 60 (33.5) | 51 (41.8) | |
| Surgery status (N (%)) | <.001 | ||
| Subtotal resection | 72 (40.2) | 76 (62.3) | |
| Gross total resection | 107 (59.8) | 46 (37.7) | |
| Concurrent radiation/TMZ (N (%)) | .015 | ||
| Yes | 118 (65.9) | 97 (79.5) | |
| No | 61 (34.1) | 25 (20.5) | |
| KPS (N (%)) | <.001 | ||
| <70 | 59 (33.0) | 16 (13.1) | |
| ≥70 | 120 (67.0) | 106 (86.9) | |
| MGMT methylation (N (%)) | .745 | ||
| Yes | 79 (44.1) | 57 (46.7) | |
| No | 100 (55.9) | 65 (53.3) | |
| Follow-up months (median [IQR]) | 12.07 [5.71, 19.75] |
13.59 [7.79, 19.19] |
.128 |
| Survival status (N (%)) | <.001 | ||
| Alive | 16 (8.9) | 31 (25.4) | |
| Dead | 163 (91.1) | 91 (74.6) |
IQR = interquartile range; TMZ = temozolomide.